Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel
NASDAQ:CTSO

Cytosorbents Q1 2026 Earnings Report

Cytosorbents logo
$0.59 -0.02 (-2.66%)
As of 01:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cytosorbents EPS Results

Actual EPS
N/A
Consensus EPS
-$0.06
Beat/Miss
N/A
One Year Ago EPS
N/A

Cytosorbents Revenue Results

Actual Revenue
N/A
Expected Revenue
$9.40 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cytosorbents Announcement Details

Quarter
Q1 2026
Date
5/13/2026
Time
After Market Closes
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Cytosorbents Earnings Headlines

CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
April 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/cytosorbents-to-report-first-quarter-2026-financial-results-and-recent-business-highlights-302758487.html
CytoSorbents Corporation
April 16, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/CTSO
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 6 at 1:00 AM  |  American Alternative (Ad)
CTSO: CytoSorbents Reports Strong 4th Quarter and Full Year 2025 Results
April 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/ctso-cytosorbents-reports-strong-4th-094200501.html
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2025 earnings call transcript
March 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/cytosorbents-corporation-nasdaqctso-q4-2025-earnings-call-transcript/ar-AA1ZxmW4
Cytosorbents (CTSO) Q4 2025 Earnings Transcript
March 26, 2026  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/03/26/cytosorbents-ctso-q4-2025-earnings-transcript/
See More Cytosorbents Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cytosorbents? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytosorbents and other key companies, straight to your email.

About Cytosorbents

Cytosorbents (NASDAQ:CTSO), founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America. In the United States, the device received Emergency Use Authorization from the U.S. Food and Drug Administration for treatment of critically ill COVID-19 patients exhibiting a cytokine storm. Clinicians integrate CytoSorb into standard extracorporeal circuits such as continuous renal replacement therapy (CRRT) and cardiopulmonary bypass to optimize blood purification protocols in intensive care units.

Beyond its core sorbent technology, Cytosorbents is advancing a pipeline of next-generation products aimed at drug overdose management and vaccine adjuvant development. The company’s R&D efforts leverage proprietary polymer bead platforms to broaden the applications of hemoadsorption in pharmaceutical safety and immunotherapy. With a global sales and distribution network and strategic partnerships in key markets, Cytosorbents continues to expand clinical evidence to support broader adoption of its blood purification solutions.

View Cytosorbents Profile
Earnings Tools